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Biallelic PDE6C mutations are a known cause for rod monochromacy, better known as 
autosomal recessive achromatopsia (ACHM), and early-onset cone photoreceptor 
dysfunction. PDE6C encodes the catalytic ´-subunit of the cone photoreceptor 
phosphodiesterase, thereby constituting an essential part of the phototransduction cascade. 
Here, we present the results of a study comprising 176 genetically pre-selected patients 
who remained unsolved after Sanger sequencing of the most frequent genes accounting for 
ACHM, and were subsequently screened for exonic and splice site variants in PDE6C 
applying a targeted next generation sequencing approach. We were able to identify 
potentially pathogenic biallelic variants in 15 index cases. The mutation spectrum comprises 
18 different alleles, 15 of which are novel. Our study significantly contributes to the 
mutation spectrum of PDE6C and allows for a realistic estimate of the prevalence of PDE6C 
mutations in ACHM since our entire ACHM cohort comprises 1074 independent families. 
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Achromatopsia (ACHM; ACHM2 MIM# 216900, ACHM3 MIM# 262300, ACHM4 MIM# 
613856, ACHM5 MIM# 613093, ACHM6 MIM# 610024, ACHM7 MIM# 616517) is a rare 
autosomal recessive cone disorder characterized by color vision defects, photophobia, 
nystagmus, and severely reduced visual acuity. To date, six genes have been linked to 
ACHM. In the Western population approximately 80% of the patients carry mutations in the 
genes CNGA3 (MIM# 600053) (Kohl et al., 1998) and CNGB3 (MIM# 605080) (Kohl et al., 
2000; Sundin et al., 2000) encoding the two subunits of the cone photoreceptor cyclic 
nucleotide-gated channel. Much less frequently, causative mutations have been found in 
genes encoding other crucial components of the cone phototransduction cascade, namely 
GNAT2 (MIM# 139340) (Aligianis et al., 2002; Kohl et al., 2002), PDE6C (MIM# 600827) 
(Chang et al., 2009; Thiadens et al., 2009), and PDE6H (MIM# 601190) (Kohl et al., 2012), or 
in ATF6 (MIM# 605537) (Kohl et al., 2015), which is not involved in the phototransduction 
cascade, but in the unfolded protein response pathway. Larger case series or genetic 
screens of ACHM-associated genes are sparse (Kohl et al., 2005; Nishiguchi, Sandberg, Gorji, 
Berson, & Dryja, 2005; Wissinger et al., 2001; Zelinger et al., 2015; Mayer et al. 2017), 
therefore we lack a comprehensive view of the prevalence especially of the minor disease 
genes in ACHM.  
In the present study, 176 patients diagnosed with ACHM who remained unsolved after 
Sanger sequencing of the most frequent genes accounting for ACHM, namely CNGB3, 
CNGA3, and GNAT2, were screened for exonic and splice site variants in the PDE6C gene. 
Samples from all patients and family members were recruited in accordance with the 
principles of the Declaration of Helsinki and were obtained with written informed consent 
accompanying the patients´ samples. The study was approved by the institutional review 
board of the Ethics Committee of the University Hospital of Tuebingen.  
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While two patients were screened using a custom capture panel targeting 105 retinal 
disease genes including PDE6C (Glöckle et al. 2014), the others were analyzed by means of 
an amplicon-based next generation sequencing approach. Briefly, target enrichment of 
coding sequences including exon-intron boundaries of PDE6C (Supp. Table S1) was 
performed with Fluidigm 48.48 Access Arrays. Library capture was completed using the 
Nextera XT DNA Library Prep Kit and sequencing was performed on a MiSeq instrument at a 
core facility (c.ATG, Tübingen). Sequence data were aligned using the Burrows-Wheeler 
Aligner (Li & Durbin, 2009), and variants were called using an in-house bioinformatic 
pipeline. Only non-synonymous single nucleotide variants, nonsense variants, splice site 
(±10 bps) variants, insertions, duplications and deletions represented by more than 20 
sequence reads were considered for further analysis. In addition, variants with a minor 
allele frequency (MAF) >1% in the Genome Aggregation Database (gnomAD) Version r2.0.2 
were excluded from further investigation. The potential pathogenicity of missense changes 
was assessed using five online prediction software tools, namely SIFT (https://sift.jcvi.org/) 
(Kumar, Henikoff, & Ng, 2009), PolyPhen-2 (https://genetics.bwh.harvard.edu/pph2/) 
(Adzhubei et al., 2010), Mutation Taster (https://www.mutationtaster.org/) (Schwarz, 
Cooper, Schuelke, & Seelow, 2014), Mutation Assessor (http://mutationassessor.org/r3/) 
(Reva, Antipin, & Sander, 2011) and Provean (http://provean.jcvi.org) (Choi & Chan, 2015). 
Prediction outcomes are given in Suppl. Table S2. The variant designation is based on the 
NCBI reference sequence for PDE6C (NC_000010.11, NM_006204.3; GRCh38) comprising 22 
coding exons. We were able to identify potentially pathogenic biallelic variants in 15 index 
cases, thereby achieving a detection rate of 8.5%. All putative disease-associated variants in 
the PDE6C gene were validated and tested for segregation with the phenotype in available 
family members by conventional Sanger sequencing. The variants were seen in true 
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homozygous state in two patients and in apparent homozygous state in seven patients, 
respectively (Supp. Table S3). Compound heterozygosity was observed for two patients 
based on the analysis of paternal alleles. In one patient, trans configuration of variants was 
established by allelic cloning. Compound heterozygosity could not be demonstrated for 
three patients because DNA of family members was not available and the respective 
variants were located too far apart for allelic cloning. The mutation spectrum comprises 18 
different alleles, 15 of which are novel (Table 1). All novel variants were deposited to the 
ClinVar database (https://www.ncbi.nlm.nih.gov/clinvar/) (Landrum et al., 2014) with 
accession codes provided in Table 1. The location of the variants identified in this study with 
respect to the PDE6C protein is depicted in Figure 1A.  
All index patients harboured unique PDE6C genotypes with the exception of the missense 
variant p.I714N which was found in homozygous state in three independent patients. In 
gnomAD this variant is present in heterozygous state in only one single subject (1/245,508 
alleles). The fact that we saw it in three independent patients was therefore indicative of a 
founder effect. Genotyping of microsatellite and SNP markers indeed revealed a common 
haplotype for the three patients (see Supp- Figure S1). 
Potential pathogenicity of variants was determined on the basis of: (1) representing 
ultrarare alleles observed only in single cases or being absent in 277,264 general population 
alleles in gnomAD; (2) in the case of missense variants being predicted to be damaging by at 
least four out of five effect prediction programs listed above; (3) representing likely null 
alleles (nonsense, canonical splice site and frameshift variants); (4) having already been 
described to be pathogenic; and (5) analysed functionally (p.R29W; Grau et al. 2011). All 
variants were classified according to their pathogenicity based on the American College of 
Medical Genetics and Genomics (ACMG) guidelines (Richards et al. 2015) (see Table 1). Since 
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nonsense, canonical splice site and frame-shifting variants have a strong weight in the 
ACMG scoring system, this class of variants are consequently classified either as likely 
pathogenic or pathogenic. An exception is the known non-canonical splice site variant 
c.939+5G>A (Abouelhoda et al., 2016), which is classified as a variant of unknown 
significance (VUS) since the +5 position is not invariable. 
All missense variants we identified have an extremely low MAF or are even absent in 
gnomAD. In addition, their evolutionary conservation and localization as well as the type of 
the respective amino acid substitution are strong indicators of pathogenicity. However, 
following the ACMG guidelines, seven of the eight missense variants we identified are 
classified as VUS. This classification would only change to pathogenic if functional data (e.g. 
of an enzymatic acitivity assay) were supportive of a damaging effect as is the case for the 
p.R29W variant (Grau et al., 2011). 
A summary of clinical findings is shown in Supp. Table S3 including all index patients and two 
affected siblings (patients 1-1 and 1-2). All patients were diagnosed in early childhood 
(ranging from birth to 5 years) and displayed characteristics of ACHM like photophobia, 
nystagmus and impaired color vision. Electroretinography (ERG) results were not available 
from every patient but generally revealed normal rod responses and either extinguished or 
severely reduced cone responses with the exception of patient 6 in whom ERG recordings 
also showed reduced b-waves in the scotopic ERG and an electronegative standard flash. 
We therefore re-classified his diagnosis from ACHM to cone-rod dystrophy. Optical 
coherence tomography (OCT) images were only available from six patients and revealed the 
typical disappearance of P2 (photoreceptor reflectivity) in patients with ACHM (Barthelmes, 
Sutter, Kurz-Levin, Bosch, Helbig, Niemeyer, & Fleischhauer, 2006).  
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The Human Gene Mutation Database currently lists 38 variants in PDE6C that explain the 
disease phenotype in the respective patients. Our study significantly contributes to the 
mutation spectrum of PDE6C and allows for a realistic estimate of the prevalence of PDE6C 
mutations in ACHM in the European population since our entire cohort comprises 1074 
independent families mainly originating from Europe or being of European descent (USA, 
Canada, Australia, New Zealand). Considering an estimated prevalence of 1:30.000 to 
1:50.000 for ACHM in Europe, this number is certainly high enough to give a comprehensive 
view on the spectrum and prevalence not only of the more common CNGB3 and CNGA3 
mutations, but also on the four minor, non-CNG channel encoding ACHM genes. Taking 
together the results of the present study and a previous screening approach (Grau et al. 
2011), we calculate a prevalence of 2.4% for PDE6C mutations in our cohort which is most 
probably representative for ACHM in the Western population (Figure 1B). As ACHM is in the 
focus of retinal gene therapy with four clinical trials ongoing, our study provides a valuable 
resource for putative gene therapy trials targeting PDE6C. 
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FIGURE 1 Localization and prevalence of PDE6C variants. A: Localization of protein 
truncating (nonsense, frame-shifting) (in red/gray) and missense variants (in black) 
identified in this study. The relative position of the three splice site variants is indicated with 
black stars. A comparative sequence analysis is given below the missense variants, showing 
conservation of the respective cone photoreceptor specific PDE6C amino acid residue 
according to HomoloGene (https://www.ncbi.nlm.nih.gov/homologene/). In addition, the 
respective amino acid residues in human rod photoreceptor PDE6A and PDE6B are shown. 
NCBI reference sequences are as follows: D. rerio (NP_957165.1), B. taurus (NP_776844.1), 
M. musculus (NP_291092.1), C. lupus (XP_543934.3), H. sapiens (NP_006195.3), H. sapiens 
PDE6A (NP_000431.2), H. sapiens PDE6B (NP_000274.2) B: Prevalence of mutations in genes 
causing ACHM relating to our cohort of 1074 independent families. Mutations in 
approximately 25% of ACHM cases remain to be identified, or clinical diagnosis 
recapitulated. 
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Table 1: Sequence variants in PDE6C               
Nucleotide (NM_006204.3) PDE6C protein (NP_006195.3) Reference(s) 
ClinVar accession 




variantsa ACMGb ACMG predictionc gnomAD MAF 
c.939+5G>A n.a.d (p.F290_E314del) Abouelhoda et al., 2016 RCV000171185.1 n.a.   PM2;PM4;PP3 VUS None 
c.1004+1G>A n.a.d (p.E314Dfs*11) Huang et al., 2013 n.a. n.a. 
 
PM2;PVS1;PP3 Pathogenic (Ic) 0.00003228 
c.1269+1G>A n.a.d (p.K374_E423del) This study SCV000678420 n.a.   PM2;PVS1;PM4 Pathogenic (Ib) None 
c.211G>T p.E71* This study SCV000678421 n.a. 
 
PM2;PVS1 Likely pathogenic (I) 0.00000813 
c.775C>T p.R259* This study SCV000678422 n.a.  PM2;PVS1 Likely pathogenic (I) 0.00000813 
c.1579C>T p.R527* This study SCV000678423 n.a. 
 
PM2;PVS1 Likely pathogenic (I) 0.0000447 
c.78del p.K27Sfs*27 This study SCV000678424 n.a.  PM2;PVS1 Likely pathogenic (I) None 
c.497del p.D166Afs*28 This study SCV000678425 n.a. 
 
PM2;PVS1 Likely pathogenic (I) None 
c.857del p.K286Rfs*16 This study SCV000678426 n.a.  PM2;PVS1 Likely pathogenic (I) None 
c.85C>T p.R29W Thiadens et al., 2009; Grau et al., 2011 SCV000086939.1 N terminal domain Damaging PM2;PM1;PP3;PS3 Pathogenic (II) 0.00002164 
c.304C>T p.R102W This study SCV000678427 GAF domain Damaging PM2;PM1;PP3 VUS None 
c.836T>C p.I279T This study SCV000678428 GAF domain Damaging PM2;PM1;PP3;PM3 Likely pathogenic (IV) 0.00001804 
c.1637C>A p.T546N This study SCV000678429 Catalytic domain Damaging PM2;PM1;PP3 VUS None 
c.2141T>A p.I714N This study SCV000678430 Catalytic domain Damaging PM2;PM1;PP3 VUS 0.00000407 
c.2156T>C p.M719T This study SCV000678431 Catalytic domain Damaging PM2;PM1;PP3 VUS 0.00006457 
c.2246G>A p.G749E This study SCV000678432 Catalytic domain Damaging PM2;PM1;PP3 VUS None 
c.2288T>C p.M763T This study SCV000678433 Catalytic domain Damaging PM2;PM1;PP3 VUS None 
c.2294A>G p.D765G This study SCV000678434 Catalytic domain Damaging PM2;PM1;PP3 VUS None 
aConsensus determined as prediction of a damaging effect by at least 4 of 5 free web-based applications (SIFT, PROVEAN, PolyPhen-2, Mutation Taster, Mutation Assessor); bcategories published in the ACMG guidelines; 
cCombination of scores leading to final classification in one of five pathogenicity categories; din silico assessment using five algorithms embedded in the Alamut software (http://www.interactive-biosoftware.com) predicted that 
skipping of the respective exon is likely. The consequence of the putative exon skipping on protein level is given in brackets. n.a., not applicable. VUS, variant of uncertain significance; MAF, minor allele frequency. 
 
 
 
 
